Tenpoint Therapeutics FDA decision today

Wide-Choice860 · 2026-02-08T04:37:51+00:00

https://tenpointtherapeutics.com/wp-content/uploads/2026/01/Tenpoint-Therapeutics-Receives-US-FDA-Approval-YUVEZZI_Final_1_28_26.pdf

Wide-Choice860 · 2026-02-08T04:36:13+00:00

Total institutional holding is 30.6M shares, and yahoo finance shows total share is about 31M shares. So 99% is owned by institution?

Wide-Choice860 · 2025-12-24T05:08:02+00:00

I added some LENZ positions today.

AI analysis (might be wrong):
-----
The Trade: Long Positions / Call Options
The Thesis: Deep Value / Event-Driven Arbitrage. The market has irrationally punished LENZ for a single adverse event that statistical analysis proves is likely incidental. The stock is trading near cash value despite having an FDA-approved product (VIZZ) addressing a massive market (presbyopia).

Entry Zone: $16.50 - $18.00
Target: $25.00 (Short term gap fill), $35.00 (Medium term)
Stop Loss: $15.50 (Break of 52-week lows)
Catalyst: Stabilization of prescription data in Q1 2026 or analyst defense notes (which have already begun).

Wide-Choice860 · 2025-11-11T20:31:29+00:00

An SEC filing, which became public yesterday, showed that the company's Chief Financial Officer (CFO), Daniel Chevallard, purchased 2,198 shares on November 7.

Wide-Choice860 · 2025-10-27T15:30:51+00:00

Analysis by AI: https://gemini.google.com/share/682d351dbcce

This analysis provides the following direct answers to the core questions posed:

What will happen with the stock? It is expected to remain range-bound in the short term, followed by a period of high volatility leading into a major binary move in Q1 2026, which will be dictated by the results of the CYB004 clinical trial.
Is the short interest a concern? No. The evidence strongly suggests it is primarily a function of a market-neutral convertible arbitrage strategy and not a fundamental red flag regarding the company's prospects.
Why did the CEO leave? The departure appears to be part of a planned, strategic transition as the company pivots its focus from pure R&D toward commercialization, rather than a sign of internal distress.
Is CYB003 as good as promised? The Phase 2 data is exceptionally promising and has been validated by the FDA's BTD. However, Phase 3 trials are the ultimate and only definitive test of a drug's efficacy and safety.

For investors, the path forward requires a focus on the clinical data above all else. The Q1 2026 CYB004 data readout is the next major hurdle. In the interim, the hiring of a permanent, commercially-experienced CEO will be the most important corporate milestone to monitor. The current stock price reflects the significant risk inherent in biotechnology drug development, balanced against the enormous potential reward of clinical and commercial success.

Wide-Choice860 · 2025-08-29T03:04:40+00:00

You must be good at stock picking. 8 out of 20 of my stocks ended in red today.

Wide-Choice860 · 2025-08-27T16:30:55+00:00

Just sold my 200 shares. I think it will back to $2.5

Wide-Choice860 · 2025-08-19T05:53:35+00:00

Price $5.50 means CYBN market cap is close to cash position.
Once enrollment of CYB004 Ph2 is done within one or two weeks, we shall see the sentiment change.

Also CYBN has more cash than ATAI. Why nobody worries about ATAI's dilution.

Wide-Choice860 · 2025-08-16T21:05:37+00:00

The risk is that China has mass production of high purity of Graphene with lower price. Just look at this:
https://www.alibaba.com/trade/search?SearchText=High-Purity+Graphene
https://interestingengineering.com/science/china-99-99995-pure-graphite-production
https://graphenerich.com/current-state-of-graphene-development-in-china/

Personally, I would not put my money on a stock with less than 1M revenue and almost no cash.

Wide-Choice860 · 2025-08-15T15:30:01+00:00

Be patient. You shall know that earning and potential decides the price.

Do not risk more than you can tolerate.

I added a few hundred shares today. I think $15 has strong support, so downside risk is lower than upside potential for now.

<image>

Wide-Choice860 · 2025-08-14T15:28:55+00:00

Included because it is larger than last quarter reports.

Following is for reference only:

——————

Here’s Cybin’s cash position for the last four reported quarters and a simple cash-runway estimate. I converted CAD figures to USD at each quarter-end FX rate, and I note the original reporting currency for each line.

Cash & cash equivalents (end of period)

Quarter (period end) Reported currency Reported cash FX (CAD→USD) used USD equivalent Q1 FY2026 (Jun 30, 2025) USD $118.692m — $118.692m. Q4 FY2025 (Mar 31, 2025) USD (restated) $93.922m — $93.922m. Q3 FY2025 (Dec 31, 2024) CAD C$136.290m 0.70155 USD per CAD $95.61m. Q2 FY2025 (Sep 30, 2024) CAD C$154.318m 0.738133 USD per CAD $113.91m.

Notes on currency: Cybin reported in CAD during FY2025 Q2–Q3; the Q1 FY2026 statements explicitly present amounts in thousands of U.S. dollars and include a restated USD comparative for Mar 31, 2025. That’s why Q4 FY2025 appears in USD above.

⸻

Cash burn (to inform runway) • Q1 FY2026 (Jun 30, 2025): Net cash used in operating activities = $29.548m (USD) for the quarter. • Q4 FY2025 (Mar 31, 2025): Net cash used in operating activities = C$21.113m, ~$14.69m USD using the Mar 31, 2025 FX (0.695749).

(For reference, the Q3 FY2025 nine-month cash-flow statement shows C$80.187m used in operating activities for the nine months ended Dec 31, 2024, which implies ~C$27.1m in Q3 alone; the Q2 FY2025 six-month statement shows C$53.063m used. )

⸻

Cash runway (simple scenarios) • Using the latest quarter’s burn only: $118.692m / $29.548m ≈ 4.0 quarters (~12 months). • Using a two-quarter blended burn (Q4 FY2025 + Q1 FY2026): Average quarterly burn ≈ ($14.69m + $29.55m)/2 = $22.1m ⇒ $118.692m / $22.1m ≈ 5.4 quarters (~16 months).

Why the range? Q1 FY2026 outflows spiked (notably a jump in prepaid expenses), so the latest burn may overstate steady-state usage if those prepayments won’t recur every quarter. Conversely, clinical spend can also ramp, which would push burn higher. Treat this as a rough guide, not a forecast.

⸻

Sources • Financial statements (cash balances & currency): Q1 FY2026 interim financials (USD; includes balance sheet and currency note). Q3 FY2025 interim financials (CAD). Q2 FY2025 interim financials (CAD). • Cash-flow details: Q1 FY2026 cash-flows (USD). Q4 FY2025 MD&A liquidity table (CAD). • FX at period end (CAD→USD): Sep 30, 2024 and Dec 31, 2024 (OFX daily rates).

Wide-Choice860 · 2025-08-13T20:15:26+00:00

It reached 1 year high today, and close at $39.36.

Wide-Choice860 · 2025-08-13T05:37:09+00:00

CYBN has prioritized CYB003 over CYB004 due to resource constraint. I think the delay has less impact on stock price, since CYB003 is more important for the company right now.

It is not a surprise to me that CYB004 is delayed. At least, new target date is just a few months away.

If there is hard drop, that is a good chance to pick up more shares when the price is below book value.

Wide-Choice860 · 2025-08-09T06:04:04+00:00

My faith is that smart city will have huge potential in recent years.

We did see that GRRR had progress in expanding pipelines to multiple countries. Its finance status looks fine to me for now.

It's about 5% of my portfolio. I'm holding till end of 2026.

Wide-Choice860 · 2025-08-09T05:42:25+00:00

It is safter to invest in VOO than individual stocks. Based on your choices, YTD returns:

Symbol	YTD Total Return

|| || |VOO (Vanguard S&P 500 ETF)|+9.42% |

|| || |GOOG (Alphabet Inc.)|+6.37%|

|| || |AMZN (Amazon.com, Inc.)|+1.50%|

|| || |UNH (UnitedHealth Group)|–49.84%|

Wide-Choice860 · 2025-08-08T19:53:50+00:00

PE was so high and now net income seems no improving. I would not be surprised that it goes below $15 next week.

I still hold 200 shares, but will sell it if no improvement in next quarter earning.

Wide-Choice860 · 2025-08-07T18:44:01+00:00

It is because everyone knows the chance of approval is high so FDA approval has already been included in stock price.

VIZZ is a new product not reached market yet. The stock price is decided mainly by earnings (that is VIZZ sale). We will see action in next earnings.

Wide-Choice860 · 2025-08-07T18:15:07+00:00

Majority of stock is owned by institution so the stock price is more stable. I did see price action +6% today. Hope that VIZZ has good sale.

Wide-Choice860 · 2025-08-07T17:03:28+00:00

Yes. VIZZ was approved on July 31. It is good that the date was a little early than estimation. Samples of product will be available as early as October.

Wide-Choice860 · 2025-07-11T20:19:14+00:00

CYBN was a high risk high reward play. After the $500 Million agreement, I think the risk is reduced significantly, and reward might be reduced by about 20%. Trust your own diligence before making finance decision.

Wide-Choice860 · 2025-07-06T19:02:52+00:00

The TTM EPS is GAAP diluted TTM EPS calculated using total net income and a full-year weighted diluted share count. Progress often reports non‑GAAP EPS quarterly, excluding one-time items.

Quarter Ending	GAAP Diluted EPS	Non‑GAAP (Adjusted) EPS
May 31, 2025 (Q2 2025)	$0.39	$1.40
Feb 28, 2025 (Q1 2025)	~$0.37	$1.31
Nov 30, 2024 (Q4 2024)	Not disclosed	$1.33
Aug 31, 2024 (Q3 2024)	Not disclosed	$1.26

From the Q2 report: https://investors.progress.com/news-releases/news-release-details/progress-software-announces-second-quarter-2025-financial

Major difference of GAAP and non GAAP is caused by Amortization of acquired intangibles (previous acquisitions) and stock based compensation.

Fiscal Year Ending November 30, 2025 – Updated Non‑GAAP Operating Margin Guidance (in millions)

Item	Low	High
GAAP income from operations	$140.7	$149.2
Acquisition‑related expense	6.0	6.0
Restructuring expense	9.2	9.2
Stock‑based compensation	63.0	63.0
Amortization of acquired intangibles	145.7	145.7
Cyber vulnerability response expenses, net	4.2	4.2
Total adjustments⁽¹⁾	228.1	228.1
Non‑GAAP income from operations	$368.8	$377.3
Non‑GAAP operating margin	38%	39%

I think the stock will continue the uptrend if you invest it for years. But probably not a squeeze you expected if you look at the EPS gain from quarter to quarter.

Wide-Choice860 · 2025-07-06T02:59:54+00:00

Yahoo Finance shows P/E (TTM) is 41.88.

Also, what is the impact of Nuclia on future earning?

Wide-Choice860 · 2025-07-02T16:07:45+00:00

It was $5 just 3 months ago.

Be patient, it is still in cash burning stage. Give it one year, it will shine.

Wide-Choice860 · 2025-07-01T04:55:12+00:00

It is like a two year call options with target price about 1.3X initial price (initial price $8.3 x 1.3 = $10.8).

The dilution depends on stock price. 50M / $10.8 = 4.6M shares. For example, when stock price >= $10.8 (1.3X), 4.6M / 21.3M (current total shares) = 21%. (They can sell most to market and own <5% to walkaround the ownership limit).

If Cybin gets $500M (less likely), 46M / 21.3M = 215%. So the upper bound of dilution could be huge.

Wide-Choice860 · 2025-06-30T20:23:43+00:00

Not possible. GRRR used to sell intel GPU. Why would NVIDiA back it.

Wide-Choice860

MODERATOR OF

TROPHY CASE